Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Prostate Cancer Drug At Center Of Takeover, Drug Price Fights

By Andy Szal | July 11, 2016

Pharmaceutical giants, advocacy groups, a biotech firm and a major research university are currently locked in disputes involving a new prostate cancer drug.

The Los Angeles Times this week detailed the saga of Xtandi, which was discovered by scientists at the University of California-Los Angeles more than a decade ago and is currently sold by San Francisco-based Medivation for some $129,000 per year.

Medivation recently entered into confidentiality agreements with Sanofi, Pfizer, Celgene and possibly others amid potential merger talks.

The firm recently rejected multi-billion dollar overtures from Sanofi, the first of which prompted the French company to mount an effort to oust Medivation’s board of directors.

The drug exemplifies the importance of new — and expensive — cancer drugs to biotech and pharmaceutical companies. But the merger talks also come amid growing health care costs in the U.S. and louder criticism of high drug prices.

Two nonprofits asked the federal government to allow other companies to sell Xtandi at lower prices. They argued, in part, that UCLA discovered the drug with help from grants funded by taxpayers.

The university and the scientists who discovered Xtandi received more than $1 billion for the rights to the drug earlier this year. More than $500 million went to UCLA — funding that is now used to support research, fellowships and scholarships.

The National Institutes of Health rejected the groups’ request last month, but they say they plan to appeal the decision and file another request after the White House changes hands next year.


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE